National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

enoxaparin
A low molecular weight, synthetic heparin. As an anticoagulant/antithrombotic agent, enoxaprin's mechanism of action is similar to that of heparin, although it exhibits a higher ratio of anti-Factor Xa to anti-Factor IIa activity. This agent also has anti-inflammatory properties, inhibiting monocyte adhesion to tumor necrosis factor alpha- or lipopolysaccharide-activated endothelial cells. Compared to unfractionated heparins, the use of enoxaparin is associated with lower incidences of osteoporosis and heparin-induced thrombocytopenia. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Synonym:Enoxaparin Sodium
US brand name:Lovenox



Previous:Emtriva, Enbrel, enclomiphene citrate, endothelin B receptor agonist SPI-1620, Enhanzyn
Next:Entereg, enteric-coated zoledronic acid tablet MER-101, Entericin, entinostat, enzastaurin hydrochloride

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov